-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SSA1aAxKP0ObPZ4IkcOCpDrkU1c935W/BuhsyTia07k5oPkWnesuGCwmPQIaTlS2
 ddqmRAj5GBgl7HXusU/q+w==

<SEC-DOCUMENT>0001209191-08-023639.txt : 20080410
<SEC-HEADER>0001209191-08-023639.hdr.sgml : 20080410
<ACCEPTANCE-DATETIME>20080410151522
ACCESSION NUMBER:		0001209191-08-023639
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080405
FILED AS OF DATE:		20080410
DATE AS OF CHANGE:		20080410

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REGEN BIOLOGICS INC
		CENTRAL INDEX KEY:			0000883697
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				232476415
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVENUE
		STREET 2:		10TH FLOOR
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2016515140

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVENUE
		STREET 2:		10TH FLOOR
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AROS CORP
		DATE OF NAME CHANGE:	20010712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APACHE MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19960426

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Bisbee Gerald JR
		CENTRAL INDEX KEY:			0001313055

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20805
		FILM NUMBER:		08749887

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		410-349-2431

	MAIL ADDRESS:	
		STREET 1:		1290 BAY DALE DRIVE
		STREET 2:		PMB 351
		CITY:			ARNOLD
		STATE:			MD
		ZIP:			21012
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2008-04-05</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000883697</issuerCik>
        <issuerName>REGEN BIOLOGICS INC</issuerName>
        <issuerTradingSymbol>RGBI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001313055</rptOwnerCik>
            <rptOwnerName>Bisbee Gerald JR</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>411 HACKENSACK AVENUE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>HACKENSACK</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07601</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chairman, President &amp; CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>STOCK OPTION (RIGHT TO BUY)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>16.00</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2008-04-05</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>25454</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2018-04-05</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Series E Convertible Preferred Stock</value>
                    <footnoteId id="F4"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>25454</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>25454</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">EXERCISE PRICE IS $0.16 PER SHARE OF COMMON STOCK IF OPTION IS EXERCISED AFTER MANDATORY CONVERSION OF SERIES E STOCK.</footnote>
        <footnote id="F2">EQUAL TO 2,545,400 SHARES OF COMMON STOCK AFTER MANDATORY CONVERSION OF THE SERIES E STOCK</footnote>
        <footnote id="F3">THE OPTION VESTS RATABLY ON A DAILY BASIS OVER FOUR YEARS FROM THE DATE OF FDA CLEARANCE OF THE COLLAGEN SCAFFOLD 510(K) APPLICATION.</footnote>
        <footnote id="F4">EACH SHARE OF SERIES E STOCK IS MANDATORILY CONVERTIBLE INTO 100 SHARES OF REGEN'S COMMON STOCK AT SUCH TIME AS (i) THE COMPANY'S CERTIFICATE OF INCORPORATION IS AMENDED TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK OR (ii) UPON THE EFFECTIVENESS OF A REVERSE STOCK SPLIT OF THE COMMON STOCK, SUCH THAT THERE ARE A SUFFICIENT NUMBER OF SHARES OF COMMON STOCK TO EFFECT THE CONVERSION.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/S/ BRION D. UMIDI ATTORNEY IN FACT</signatureName>
        <signatureDate>2008-04-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----